Skip to content

Study · Non-randomized trial · n = 21 · 2010

3 results

Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women.

Drake MT, McCready LK, Hoey KA, Atkinson EJ, Khosla S

The Journal of clinical endocrinology and metabolism7 Jul 2010Cited by 68 (Europe PMC)

PMID20610587 (opens in a new tab)PMCIDPMC2968737 (opens in a new tab)DOI10.1210/jc.2010-1103 (opens in a new tab)PepBankPUB-20610587
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal women, leuprolide reduced serum FSH by 86% from baseline.

    In plain wordsIn postmenopausal women, leuprolide reduced FSH from baseline.

    Peptide
    Leuprolide
    Outcome
    DecreaseSerum FSH
    Study

    n = 21

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    7.5 mg every 28 days · intramuscular · 105 daysAs given in this study (human).

    Measurements

    FSH change
    −86%
    leuprolide

    Source sentences

    Summary
    Compared with baseline, serum FSH levels did not change significantly in controls (+6%) but were reduced (-86%, into the premenopausal range) in the GnRH group.
    2 context sentences
    Summary · context
    Postmenopausal women were treated with a GnRH agonist (leuprolide acetate, 7.5 mg im every 28 d; n = 21) or placebo injections (control; n = 20).
    Summary · context
    Both groups received the aromatase inhibitor, letrozole, 2.5 mg/d, to eliminate variations in endogenous estrogen levels as a confounder.
  2. 02HumanNon-randomized trialEfficacy outcome

    In postmenopausal women, CTX increased by 34% with leuprolide, without a significant difference in percent change versus controls.

    In plain wordsIn postmenopausal women, CTX changes with leuprolide did not differ significantly from controls.

    Peptide
    Leuprolide
    Outcome
    No significant changeSerum CTX
    Study

    n: not reported in source

    Comparator
    Placebo with letrozole
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    7.5 mg every 28 days · intramuscular · 105 daysAs given in this study (human).

    Measurements

    CTX change
    34%
    leuprolide
    P
    0.161
    between groups

    Source sentences

    Summary
    In the GnRH group, suppression of FSH secretion did not reduce serum CTX or TRAP5b levels; rather, both markers also increased in these women (+34 and +15%, respectively; P = 0.161 and 0.266 for comparison of percent changes between groups).
    2 context sentences
    Summary · context
    Postmenopausal women were treated with a GnRH agonist (leuprolide acetate, 7.5 mg im every 28 d; n = 21) or placebo injections (control; n = 20).
    Summary · context
    Both groups received the aromatase inhibitor, letrozole, 2.5 mg/d, to eliminate variations in endogenous estrogen levels as a confounder.
  3. 03HumanNon-randomized trialEfficacy outcome

    In postmenopausal women, TRAP5b increased by 15% with leuprolide, without a significant difference in percent change versus controls.

    In plain wordsIn postmenopausal women, TRAP5b changes with leuprolide did not differ significantly from controls.

    Peptide
    Leuprolide
    Outcome
    No significant changeSerum TRAP5b
    Study

    n: not reported in source

    Comparator
    Placebo with letrozole
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    7.5 mg every 28 days · intramuscular · 105 daysAs given in this study (human).

    Measurements

    TRAP5b change
    15%
    leuprolide
    P
    0.266
    between groups

    Source sentences

    Summary
    In the GnRH group, suppression of FSH secretion did not reduce serum CTX or TRAP5b levels; rather, both markers also increased in these women (+34 and +15%, respectively; P = 0.161 and 0.266 for comparison of percent changes between groups).
    2 context sentences
    Summary · context
    Postmenopausal women were treated with a GnRH agonist (leuprolide acetate, 7.5 mg im every 28 d; n = 21) or placebo injections (control; n = 20).
    Summary · context
    Both groups received the aromatase inhibitor, letrozole, 2.5 mg/d, to eliminate variations in endogenous estrogen levels as a confounder.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.